Nautilus Biotechnology (NAUT) to Release Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, April 29th. Analysts expect Nautilus Biotechnology to post earnings of ($0.14) per share for the quarter.

Nautilus Biotechnology Stock Performance

NASDAQ NAUT traded down $0.02 on Friday, reaching $0.69. The company had a trading volume of 272,183 shares, compared to its average volume of 107,701. The firm has a market capitalization of $86.84 million, a price-to-earnings ratio of -1.23 and a beta of 1.39. The company's fifty day moving average is $1.02 and its 200-day moving average is $1.76. Nautilus Biotechnology has a 1-year low of $0.66 and a 1-year high of $3.09.

Insider Activity

In other news, CEO Sujal M. Patel purchased 53,300 shares of the business's stock in a transaction on Wednesday, March 19th. The stock was purchased at an average price of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the purchase, the chief executive officer now directly owns 10,117,788 shares in the company, valued at $10,016,610.12. The trade was a 0.53 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 40.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Nautilus Biotechnology

An institutional investor recently raised its position in Nautilus Biotechnology stock. Bank of America Corp DE grew its holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) by 37.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,419 shares of the company's stock after buying an additional 13,363 shares during the period. Bank of America Corp DE's holdings in Nautilus Biotechnology were worth $83,000 at the end of the most recent quarter. 50.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Guggenheim set a $2.50 price objective on shares of Nautilus Biotechnology in a research report on Friday, February 28th.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.